title: Safety and efficacy of the combination of T-DM1 with radiotherapy of the central nervous system in a patient with HER2-positive metastatic breast cancer: case study and review of the literature.
abstract: Approximately 35% of patients with confirmed HER2 breast cancer progress to metastases of the central nervous system (CNS). Total cerebral radiotherapy is considered as standard treatment for these cases; however, studies have shown that some chemotherapy drugs can be used during radiotherapy without significantly increasing its toxicity. In this article, we report the case of a patient with HER2-positive breast cancer who showed isolated progression of the illness in the CNS, which was observed during the treatment period using T-DM1 concomitantly with radiotherapy of the CNS without apparent toxicity of the combination and keeping the illness controlled. Through a review of the literature on the use of radiotherapy and chemotherapy with T-DM1 for the treatment of cerebral metastases in HER2-positive breast cancer, we describe the efficacy and tolerance of the concomitant application of these treatments.
authors.affiliation: Médico Novos Tratamentos Litoral (Clínica de Neoplasias Litoral), Itajaí, Santa Catarina, CRM-SC 11867, Brazil.
authors.forename: Giuliano Santos
authors.initials: GS
authors.lastname: Borges
authors.affiliation: Médico Hospital Santo Antônio, Blumenau, Santa Catarina, CRM-SC 15751, Brazil.
authors.forename: Rodrigo Kraft
authors.initials: RK
authors.lastname: Rovere
authors.affiliation: Médica Prefeitura Municipal de Balneário Camboriú, Santa Catarina, CRM-SC 21977, Brazil.
authors.forename: Stéphanie Mereniuk Kappel
authors.initials: SM
authors.lastname: Dias
authors.affiliation: Médico Plantonista, CRM-SC 21967, Brazil.
authors.forename: Fernando Henrique
authors.initials: FH
authors.lastname: Chong
authors.affiliation: Médica Prefeitura Municipal de Apiúna, Santa Catarina, CRM-SC 21955, Brazil.
authors.forename: Mayara Dos Santos
authors.initials: Mdos S
authors.lastname: Morais
keywords: HER2-positive; TDM1; breast cancer; radiotherapy